- Home
- BYSI vs VANI Comparison
BYSI vs VANI Comparison
Compare BYSI & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- VANI
- Stock Information
- Founded
- BYSI 2010
- VANI 1998
- Country
- BYSI United States
- VANI United States
- Employees
- BYSI N/A
- VANI N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BYSI Health Care
- VANI Health Care
- Exchange
- BYSI Nasdaq
- VANI Nasdaq
- Market Cap
- BYSI 71.0M
- VANI 68.1M
- IPO Year
- BYSI 2017
- VANI 2014
- Fundamental
- Price
- BYSI $2.27
- VANI $1.29
- Analyst Decision
- BYSI
- VANI Strong Buy
- Analyst Count
- BYSI 0
- VANI 1
- Target Price
- BYSI N/A
- VANI $4.00
- AVG Volume (30 Days)
- BYSI 154.5K
- VANI 141.5K
- Earning Date
- BYSI 08-11-2025
- VANI 08-12-2025
- Dividend Yield
- BYSI N/A
- VANI N/A
- EPS Growth
- BYSI N/A
- VANI N/A
- EPS
- BYSI N/A
- VANI N/A
- Revenue
- BYSI N/A
- VANI N/A
- Revenue This Year
- BYSI N/A
- VANI N/A
- Revenue Next Year
- BYSI N/A
- VANI N/A
- P/E Ratio
- BYSI N/A
- VANI N/A
- Revenue Growth
- BYSI N/A
- VANI N/A
- 52 Week Low
- BYSI $0.98
- VANI $0.91
- 52 Week High
- BYSI $3.44
- VANI $1.50
- Technical
- Relative Strength Index (RSI)
- BYSI 47.79
- VANI 60.40
- Support Level
- BYSI $2.21
- VANI $1.24
- Resistance Level
- BYSI $2.50
- VANI $1.30
- Average True Range (ATR)
- BYSI 0.30
- VANI 0.06
- MACD
- BYSI -0.09
- VANI -0.00
- Stochastic Oscillator
- BYSI 4.88
- VANI 63.64
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.